¢¸
  • Æó¿Í °£Á¶Á÷ÀÇ »êÈ­¼º ¼Õ»ó¿¡ ´ëÇÑ DeferoxamineÀÇ Ç×»êÈ­ È¿°ú¿¡ °üÇÑ ¿¬±¸   (1 ÆäÀÌÁö)
    1

  • Æó¿Í °£Á¶Á÷ÀÇ »êÈ­¼º ¼Õ»ó¿¡ ´ëÇÑ DeferoxamineÀÇ Ç×»êÈ­ È¿°ú¿¡ °üÇÑ ¿¬±¸   (2 ÆäÀÌÁö)
    2

  • Æó¿Í °£Á¶Á÷ÀÇ »êÈ­¼º ¼Õ»ó¿¡ ´ëÇÑ DeferoxamineÀÇ Ç×»êÈ­ È¿°ú¿¡ °üÇÑ ¿¬±¸   (3 ÆäÀÌÁö)
    3

  • Æó¿Í °£Á¶Á÷ÀÇ »êÈ­¼º ¼Õ»ó¿¡ ´ëÇÑ DeferoxamineÀÇ Ç×»êÈ­ È¿°ú¿¡ °üÇÑ ¿¬±¸   (4 ÆäÀÌÁö)
    4

  • Æó¿Í °£Á¶Á÷ÀÇ »êÈ­¼º ¼Õ»ó¿¡ ´ëÇÑ DeferoxamineÀÇ Ç×»êÈ­ È¿°ú¿¡ °üÇÑ ¿¬±¸   (5 ÆäÀÌÁö)
    5

  • Æó¿Í °£Á¶Á÷ÀÇ »êÈ­¼º ¼Õ»ó¿¡ ´ëÇÑ DeferoxamineÀÇ Ç×»êÈ­ È¿°ú¿¡ °üÇÑ ¿¬±¸   (6 ÆäÀÌÁö)
    6

  • Æó¿Í °£Á¶Á÷ÀÇ »êÈ­¼º ¼Õ»ó¿¡ ´ëÇÑ DeferoxamineÀÇ Ç×»êÈ­ È¿°ú¿¡ °üÇÑ ¿¬±¸   (7 ÆäÀÌÁö)
    7

  • Æó¿Í °£Á¶Á÷ÀÇ »êÈ­¼º ¼Õ»ó¿¡ ´ëÇÑ DeferoxamineÀÇ Ç×»êÈ­ È¿°ú¿¡ °üÇÑ ¿¬±¸   (8 ÆäÀÌÁö)
    8

  • Æó¿Í °£Á¶Á÷ÀÇ »êÈ­¼º ¼Õ»ó¿¡ ´ëÇÑ DeferoxamineÀÇ Ç×»êÈ­ È¿°ú¿¡ °üÇÑ ¿¬±¸   (9 ÆäÀÌÁö)
    9

  • Æó¿Í °£Á¶Á÷ÀÇ »êÈ­¼º ¼Õ»ó¿¡ ´ëÇÑ DeferoxamineÀÇ Ç×»êÈ­ È¿°ú¿¡ °üÇÑ ¿¬±¸   (10 ÆäÀÌÁö)
    10

  • Æó¿Í °£Á¶Á÷ÀÇ »êÈ­¼º ¼Õ»ó¿¡ ´ëÇÑ DeferoxamineÀÇ Ç×»êÈ­ È¿°ú¿¡ °üÇÑ ¿¬±¸   (11 ÆäÀÌÁö)
    11

  • Æó¿Í °£Á¶Á÷ÀÇ »êÈ­¼º ¼Õ»ó¿¡ ´ëÇÑ DeferoxamineÀÇ Ç×»êÈ­ È¿°ú¿¡ °üÇÑ ¿¬±¸   (12 ÆäÀÌÁö)
    12

  • Æó¿Í °£Á¶Á÷ÀÇ »êÈ­¼º ¼Õ»ó¿¡ ´ëÇÑ DeferoxamineÀÇ Ç×»êÈ­ È¿°ú¿¡ °üÇÑ ¿¬±¸   (13 ÆäÀÌÁö)
    13

  • Æó¿Í °£Á¶Á÷ÀÇ »êÈ­¼º ¼Õ»ó¿¡ ´ëÇÑ DeferoxamineÀÇ Ç×»êÈ­ È¿°ú¿¡ °üÇÑ ¿¬±¸   (14 ÆäÀÌÁö)
    14

  • Æó¿Í °£Á¶Á÷ÀÇ »êÈ­¼º ¼Õ»ó¿¡ ´ëÇÑ DeferoxamineÀÇ Ç×»êÈ­ È¿°ú¿¡ °üÇÑ ¿¬±¸   (15 ÆäÀÌÁö)
    15


  • º» ¹®¼­ÀÇ
    ¹Ì¸®º¸±â´Â
    15 Pg ±îÁö¸¸
    °¡´ÉÇÕ´Ï´Ù.
¢º
Ŭ¸¯ : ´õ Å©°Ôº¸±â
  • Æó¿Í °£Á¶Á÷ÀÇ »êÈ­¼º ¼Õ»ó¿¡ ´ëÇÑ DeferoxamineÀÇ Ç×»êÈ­ È¿°ú¿¡ °üÇÑ ¿¬±¸   (1 ÆäÀÌÁö)
    1

  • Æó¿Í °£Á¶Á÷ÀÇ »êÈ­¼º ¼Õ»ó¿¡ ´ëÇÑ DeferoxamineÀÇ Ç×»êÈ­ È¿°ú¿¡ °üÇÑ ¿¬±¸   (2 ÆäÀÌÁö)
    2

  • Æó¿Í °£Á¶Á÷ÀÇ »êÈ­¼º ¼Õ»ó¿¡ ´ëÇÑ DeferoxamineÀÇ Ç×»êÈ­ È¿°ú¿¡ °üÇÑ ¿¬±¸   (3 ÆäÀÌÁö)
    3

  • Æó¿Í °£Á¶Á÷ÀÇ »êÈ­¼º ¼Õ»ó¿¡ ´ëÇÑ DeferoxamineÀÇ Ç×»êÈ­ È¿°ú¿¡ °üÇÑ ¿¬±¸   (4 ÆäÀÌÁö)
    4

  • Æó¿Í °£Á¶Á÷ÀÇ »êÈ­¼º ¼Õ»ó¿¡ ´ëÇÑ DeferoxamineÀÇ Ç×»êÈ­ È¿°ú¿¡ °üÇÑ ¿¬±¸   (5 ÆäÀÌÁö)
    5

  • Æó¿Í °£Á¶Á÷ÀÇ »êÈ­¼º ¼Õ»ó¿¡ ´ëÇÑ DeferoxamineÀÇ Ç×»êÈ­ È¿°ú¿¡ °üÇÑ ¿¬±¸   (6 ÆäÀÌÁö)
    6

  • Æó¿Í °£Á¶Á÷ÀÇ »êÈ­¼º ¼Õ»ó¿¡ ´ëÇÑ DeferoxamineÀÇ Ç×»êÈ­ È¿°ú¿¡ °üÇÑ ¿¬±¸   (7 ÆäÀÌÁö)
    7

  • Æó¿Í °£Á¶Á÷ÀÇ »êÈ­¼º ¼Õ»ó¿¡ ´ëÇÑ DeferoxamineÀÇ Ç×»êÈ­ È¿°ú¿¡ °üÇÑ ¿¬±¸   (8 ÆäÀÌÁö)
    8

  • Æó¿Í °£Á¶Á÷ÀÇ »êÈ­¼º ¼Õ»ó¿¡ ´ëÇÑ DeferoxamineÀÇ Ç×»êÈ­ È¿°ú¿¡ °üÇÑ ¿¬±¸   (9 ÆäÀÌÁö)
    9

  • Æó¿Í °£Á¶Á÷ÀÇ »êÈ­¼º ¼Õ»ó¿¡ ´ëÇÑ DeferoxamineÀÇ Ç×»êÈ­ È¿°ú¿¡ °üÇÑ ¿¬±¸   (10 ÆäÀÌÁö)
    10



  • º» ¹®¼­ÀÇ
    (Å« À̹ÌÁö)
    ¹Ì¸®º¸±â´Â
    10 Page ±îÁö¸¸
    °¡´ÉÇÕ´Ï´Ù.
´õºíŬ¸¯ : ´Ý±â
X ´Ý±â
µå·¡±× : Á¿ìÀ̵¿

Æó¿Í °£Á¶Á÷ÀÇ »êÈ­¼º ¼Õ»ó¿¡ ´ëÇÑ DeferoxamineÀÇ Ç×»êÈ­ È¿°ú¿¡ °üÇÑ ¿¬±¸

·¹Æ÷Æ® > °øÇбâ¼ú ÀÎ ¼â ¹Ù·Î°¡±âÀúÀå
Áñ°Üã±â
Å°º¸µå¸¦ ´­·¯ÁÖ¼¼¿ä
( Ctrl + D )
¸µÅ©º¹»ç
Ŭ¸³º¸µå¿¡ º¹»ç µÇ¾ú½À´Ï´Ù.
¿øÇÏ´Â °÷¿¡ ºÙÇô³Ö±â Çϼ¼¿ä
( Ctrl + V )
ÆÄÀÏ : Æó¿Í °£Á¶Á÷ÀÇ »êÈ­¼º ¼Õ»ó¿¡ ´ëÇÑ DeferoxamineÀÇ Ç×~.hwp   [Size : 61 Kbyte ]
ºÐ·®   37 Page
°¡°Ý  3,000 ¿ø

Ä«Ä«¿À ID·Î
´Ù¿î ¹Þ±â
±¸±Û ID·Î
´Ù¿î ¹Þ±â
ÆäÀ̽ººÏ ID·Î
´Ù¿î ¹Þ±â


ÀÚ·á¼³¸í
»êÈ­Á¦´Â »ê¼ÒÀÇ ºÒ¾ÈÁ¤ÇÑ ´ë»ç»ê¹°·Î¼­ °­·ÂÇÑ »êÈ­¼º ÀÛ¿ëÀ» Áö´Ï°í ÀÖÀ¸¸ç, °ú»êÈ­¹°(02-), °ú»êÈ­¼ö¼Ò ¹× ¼ö»ê±â( OH⋅) µîÀÌ ...
º»¹®/³»¿ë
»êÈ­Á¦´Â »ê¼ÒÀÇ ºÒ¾ÈÁ¤ÇÑ ´ë»ç»ê¹°·Î¼­ °­·ÂÇÑ »êÈ­¼º ÀÛ¿ëÀ» Áö´Ï°í ÀÖÀ¸¸ç, °ú»êÈ­¹°(02-), °ú»êÈ­¼ö¼Ò ¹× ¼ö»ê±â( OH⋅) µîÀÌ Àִµ¥ ÆÐÇ÷Áõ, ÇãÇ÷-Àç°ü·ù, È­»ó µîÀÇ Áúȯ¿¡¼­ ¸¹ÀÌ ºÐºñµÇ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù(Cross et al., 1987; Heffner & Repine, 1989; Reilly et al., 1991). ÀÌµé ¹°ÁúµéÀº ¼¼Æ÷¸·ÀÇ ±¸¼º¼ººÐÀÎ ÁöÁúÀ» °ú»êÈ­½ÃÄѼ­ ¼¼Æ÷¸·ÀÇ ¼Õ»ó°ú ´õºÒ¾î ¼¼Æ÷³» ±â´É»ó½ÇÀ» À¯¹ß½ÃŲ´Ù. ÀÌ·¯ÇÑ »êÈ­Á¦¿¡ ÀÇÇÑ ÆóÁ¶Á÷ÀÇ ÁöÁú°ú»êÈ­´Â È­»óÀ» ºñ·ÔÇÑ ¿©·¯ µ¿¹°½ÇÇè¸ðµ¨¿¡¼­ Áõ¸íµÇ¾ú´Ù(Jin et al., 1986; Demling & Lalonde, 1990; Demling et al., 1991). Paraquat(1,1`-dimethyl-4, 4-bipyridylium dichloride)´Â 1958³â ¿µ±¹¿¡¼­ óÀ½À¸·Î Á¦ÃÊÁ¦·Î »ç¿ëµÈ ÀÌ·¡ Àü¼¼°èÀûÀ¸·Î ³Î¸® »ç¿ëµÇ¾îÁ® ¿Ô´ø ¾àÁ¦·Î, »ç¶÷°ú µ¿¹°ÀÌ Áßµ¶½Ã µ¶¼ºÀÌ Ä¡¸íÀûÀÎ °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. Paraquat¸¦ À½µ¶½Ã ¹®Á¦°¡ µÇ´Â °ÍÀº Ä¡·áÁ¦·Î¼­ Ưº°ÇÑ Çص¶Á¦°¡ ¾ø´Ù´Â »ç½Ç°ú À½µ¶ ÈÄ Á¶±âÀÇ Àû±ØÀûÀÎ Ä¡·á, ¿¹¸¦ µé¸é Àå¿¡¼­ÀÇ Èí¼ö¸¦ ÁÙÀ̱â À§ÇÏ¿© À§À弼ô, ±¸Åä, È°¼ºÅº Åõ¿© µîÀÇ ¹æ¹ý°ú, Èí¼öµÈ Ç÷Áß³»ÀÇ paraquatÀ» Á¦°ÅÇϱâ À§ÇÏ¿© º¹¸·Åõ¼®, Ç÷¾×Åõ¼®, hemoperfusion,¡¦(»ý·«)
Âü°í¹®Çå
Beers RF, Sizer IW. A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. J Bio Chem. 1952, 195:133.

Bismuth C, Scherrmann JM, Garnier R, et al. Elimination of paraquat. Human Toxicol. 1987, 6:63-67.

Burkitt MJ, Kadiiska MB, Hanna PM, et al. Electron spin resonance spin-trapping investigation into the effects of paraquat and deferoxamine on hydroxyl radical generation during acute iron poisoning. Molecular Pharmacology. 1992, 43:257-263.

Cross CE. Oxygen radicals and human disease. Ann Int Med. 1987, 107:526-545.

Demling R, Lalonde C. Early postburn lipid peroxidation : effects of ibuprofen and allopurinol. Surgery. 1990, 107:85-93.

Demling R, Lalonde C. Early burn excision attenuates the postburn lung and systemic response to endotoxin. Surgery. 1990, 108:28-35.

Demling R, Lalonde C, Knox J, et al. Fluid resuscitation with deferoxamine prevents systemic burn-induced oxidant injury. J Trauma. 1991, 31:538-544.

Demling R, Seekamp A, Lalonde c, et al. Catalase prevents prostanoid release and lung lipid peroxidation after endotoxemia in sheep. J Appl Physiol. 1988, 65:1210-1216.

Deneki S, Berkley AL, Fanburg B. Transient depletion of lung glutathione by diethylmaleate enhance oxygen toxicity. J Appl Physiol. 1985, 58:571-574.

Griffith OW. Determination of glutathione and glutathine sulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem. 1980, 106:207-212.

Hallaway PE, Eaton J, Panter S, et al. Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers. Proc Natl Acad Sci. 1989, 86:10108-12.

Halliwell B. Oxidants and human disease, some new concepts. FASEB. 1987, 1:358-364.

Heffer JE, Repine JE. Pulmonary strategies of antioxidant defense. Am Rev Resp Dis. 1989, 140:531-554.

Higenbottam T, Crome P, Parkinson C, et al. Further clinical observations on the pulmonary effects of paraquat ingestion. Thorax. 1979, 34:161-165.

Hudson M, Patel SB, Ewen SWB, et al. Paraquat induced pulmonary fibrosis in three survivors. Thorax. 1991, 46:201-204.

Im JG, Lee KS, Han MC, et al. Paraquat poisoning: findings on chest radiography and CT in 42 patients. AJR. 1991, 157:697-701.

Jin LJ, Lalonde C, Demling R. Lung dysfunction after thermal injury in relation to prostanoid and oxygen radical release. J Appl Physiol. 1986, 61:103-112.

Keller GA, Barke R, Harty JT. Decreased hepatic glutathione levels in septic shock. Arch Surg. 1985, 120:941-945.

Kohen R, Chevion M. Paraquat toxicity is enhanced by iron and reduced by deferrioxamine in laboratory mice. Biochem Pharmacol. 1985, 34:1841-1843.

Kosugi I, Tajimi K, Ohmura A, et al. New approachs to shock therapy: Reduced glutathione(GSH). Molecular & cellular aspects of shock & trauma. Alan R Liss, Inc, New York. 1983, 253-269.

Lheureux P, Leduc D, Vanbinst R, et al. Survival in a case of massive paraquat ingestion. Chest. 1995, 107:285-89.

Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979, 95:351-358.

Proudfoot AT, Prescott LF, Jarvie DR. Hemodialysis for paraquat poisoning. Human Toxicol. 1987, 6:69-74.

Reilly PM, Schiller HJ, Bulkley GB. Pharmacologic approach to tissue injury mediated by free radical and other reactive oxygen metabolites. Am J Surg. 1991, 161:488-503.

Van der wal NAA, Van oirscchot JFLM, Van dijk AV, et al. Mechanism of protection of alvelolar type II cells against paraquat-induced cytotoxicity by deferoxamine. Biochem Pharmacol. 1990, 39:1665-1671.

Van der wal NAA, Smith LL, Van oirschot JFLM, et al. Effect of iron chelators on paraquat toxicity in rats and alveolar type II cells. Am Rev Respir Dis. 1992, 145:180-186.

Vaziri ND, Ness RL, Fairshter RD, et al. Nephrotoxicity of paraquat in man. Arch Intern Med. 1979, 139:172-174.

Ward P, Till G, Hatherhill J, et al. Systemic complement activation and products of lipid peroxidation. J Clin Invest. 1985, 176:517-527.

White CW, Jackson JH, McMurty IF, et al. Hypoxia increases glutathione redox cycle and products rat lungs against oxidants. J Appl Physiol. 1988, 65:2607-2616.

White CW, Ghezzi P, McMahons S, et al. Cytokines increase rat lung antioxidant enzymes during exposure to hyperoxia. J Appl Physiol. 1989, 66:1003-1007.

Yam j, Roberts RJ. Pharmacological alteration of oxygen induced lung toxicity. Toxico Appl Pharmacol. 1979, 47:367-375.

Youn YK, Lalonde C, Demling R. The role of mediators in the response to thermal injury. World J Surg. 1992, 16:30-36.


ÀÚ·áÁ¤º¸
ID : skil******
Regist : 2012-07-12
Update : 2012-07-12
FileNo : 16034266

Àå¹Ù±¸´Ï

¿¬°ü°Ë»ö(#)
°£Á¶Á÷   »êÈ­¼º   ¼Õ»ó¿¡   ´ëÇÑ   Deferoxamine   Ç×»êÈ­   È¿°ú¿¡   °üÇÑ   ¿¬±¸  


ȸ»ç¼Ò°³ | °³ÀÎÁ¤º¸Ãë±Þ¹æħ | °í°´¼¾ÅÍ ¤Ó olle@olleSoft.co.kr
¿Ã·¹¼ÒÇÁÆ® | »ç¾÷ÀÚ : 408-04-51642 ¤Ó ±¤ÁÖ±¤¿ª½Ã ±¤»ê±¸ ¹«Áø´ë·Î 326-6, 201È£ | äÈñÁØ | Åë½Å : ±¤»ê0561È£
Copyright¨Ï ¿Ã·¹¼ÒÇÁÆ® All rights reserved | Tel.070-8744-9518
°³ÀÎÁ¤º¸Ãë±Þ¹æħ ¤Ó °í°´¼¾ÅÍ ¤Ó olle@olleSoft.co.kr
¿Ã·¹¼ÒÇÁÆ® | »ç¾÷ÀÚ : 408-04-51642 | Tel.070-8744-9518